CIK 0001626971
- Non-accelerated filer
- Smaller reporting company
Corvus Pharmaceuticals, Inc.
Sign in to watch- Ticker
- CRVS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464670809
- Phone
- +1 650-900-4520
- Business address
- 901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy President and CEO bought 20,000 shares at $3.29 ($65,884)
- 4 Open-market buy Chief Financial Officer bought 24,700 shares at $4.15 ($102,409)
- 4 Open-market buy President and CEO bought 10,000 shares at an average $4.40 ($43,950)
- 4 Derivatives Options or other derivatives
- 4 Gift President and CEO gave 20,000 shares (gift)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy President and CEO bought 5,000 shares at $5.99 ($29,934)
- 4 Open-market buy President and CEO bought 1,502 shares at $5.95 ($8,937)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 588,235 shares at $8.50 ($4,999,998)
- 4 Open-market buy Director bought 588,235 shares at $8.50 ($4,999,998)
Page 9 of 13 · 252 filings